HilleVax, Inc. (NASDAQ:HLVX – Get Free Report) saw a large increase in short interest in June. As of June 15th, there was short interest totalling 1,550,000 shares, an increase of 14.8% from the May 31st total of 1,350,000 shares. Approximately 9.3% of the company’s shares are sold short. Based on an average daily volume of 177,600 shares, the short-interest ratio is presently 8.7 days.
HilleVax Price Performance
Shares of HLVX opened at $14.46 on Monday. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.11. The stock has a 50 day moving average of $13.59 and a 200 day moving average of $14.89. HilleVax has a 12 month low of $9.94 and a 12 month high of $20.22.
HilleVax (NASDAQ:HLVX – Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.13). As a group, analysts expect that HilleVax will post -3.14 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Read Our Latest Report on HLVX
Insider Activity at HilleVax
In related news, Director Aditya Kohli sold 6,000 shares of the company’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $14.93, for a total transaction of $89,580.00. Following the sale, the director now owns 801,776 shares in the company, valued at approximately $11,970,515.68. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other HilleVax news, Director Aditya Kohli sold 6,000 shares of the stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $14.93, for a total value of $89,580.00. Following the transaction, the director now owns 801,776 shares in the company, valued at $11,970,515.68. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Life Sciences X. L.P. Frazier purchased 8,850 shares of the business’s stock in a transaction on Thursday, April 4th. The stock was purchased at an average price of $14.50 per share, for a total transaction of $128,325.00. Following the acquisition, the insider now owns 8,544,187 shares of the company’s stock, valued at approximately $123,890,711.50. The disclosure for this purchase can be found here. Insiders have sold a total of 24,898 shares of company stock worth $369,986 in the last 90 days. Corporate insiders own 71.10% of the company’s stock.
Institutional Trading of HilleVax
A number of institutional investors and hedge funds have recently modified their holdings of the business. Federated Hermes Inc. increased its position in shares of HilleVax by 80.6% during the third quarter. Federated Hermes Inc. now owns 2,113 shares of the company’s stock valued at $28,000 after acquiring an additional 943 shares during the last quarter. EntryPoint Capital LLC purchased a new stake in HilleVax in the first quarter worth $80,000. Swiss National Bank increased its position in HilleVax by 22.4% in the fourth quarter. Swiss National Bank now owns 38,200 shares of the company’s stock worth $613,000 after buying an additional 7,000 shares during the last quarter. SG Americas Securities LLC purchased a new stake in HilleVax in the fourth quarter worth $139,000. Finally, Tidal Investments LLC purchased a new stake in HilleVax in the first quarter worth $207,000. 86.42% of the stock is owned by hedge funds and other institutional investors.
HilleVax Company Profile
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
Featured Stories
- Five stocks we like better than HilleVax
- How to Calculate Return on Investment (ROI)
- Chewy Stock Surges on Roaring Kitty’s Disclosure of Major Stake
- Low PE Growth Stocks: Unlocking Investment Opportunities
- How to Invest in Gold: A Complete Guide
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 Stocks Wall Street Could Be Watching on Fannie Mae’s Rally
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.